Registrational trials for Covid-19 vaccines will have a number of operational obstructions, even upon agreement that they may only need to reach the lowest success bar of 50% protection over at least six months to be deemed a success.

At the beginning of the month, Moderna made several announcements, including that it was completing the design of its Phase III, expected in summer, and that its share price that day peaked at 14%. Read more here.